CYP19A1 and breast cancer: Palbociclib’s therapeutic benefits for breast cancer may be hindered by higher Ki-67 expression, primary resistance to ETs, liver metastases, multiple metastatic sites, later line of therapy, and the use of fulvestrant instead of aromatase inhibitors.